Principal Financial Group Inc. raised its stake in Aratana Therapeutics, Inc. (NASDAQ:PETX) by 0.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 391,385 shares of the biopharmaceutical company’s stock after buying an additional 124 shares during the quarter. Principal Financial Group Inc. owned approximately 1.03% of Aratana Therapeutics worth $2,830,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PETX. Vanguard Group Inc. lifted its stake in Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after buying an additional 235,208 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 203,738 shares during the last quarter. General American Investors Co. Inc. lifted its stake in Aratana Therapeutics by 18.0% in the second quarter. General American Investors Co. Inc. now owns 618,660 shares of the biopharmaceutical company’s stock valued at $4,473,000 after buying an additional 94,201 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Aratana Therapeutics by 85.7% in the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 59,181 shares during the last quarter. Finally, AWM Investment Company Inc. lifted its stake in Aratana Therapeutics by 5.7% in the first quarter. AWM Investment Company Inc. now owns 1,062,620 shares of the biopharmaceutical company’s stock valued at $5,632,000 after buying an additional 57,620 shares during the last quarter. Institutional investors own 73.04% of the company’s stock.

Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) opened at 6.37 on Friday. Aratana Therapeutics, Inc. has a 1-year low of $4.97 and a 1-year high of $9.90. The company’s market capitalization is $273.92 million. The firm has a 50-day moving average price of $5.93 and a 200-day moving average price of $6.18.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The firm had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. During the same period in the prior year, the business posted $0.61 earnings per share. The business’s revenue was down 86.4% compared to the same quarter last year. Equities analysts anticipate that Aratana Therapeutics, Inc. will post ($1.09) earnings per share for the current year.

In other news, insider Ernst Heinen sold 10,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $6.25, for a total transaction of $62,500.00. Following the sale, the insider now owns 130,994 shares in the company, valued at $818,712.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $6.24, for a total value of $312,000.00. The disclosure for this sale can be found here. Insiders have sold 70,000 shares of company stock worth $435,600 in the last 90 days. Company insiders own 5.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Principal Financial Group Inc. Grows Holdings in Aratana Therapeutics, Inc. (PETX)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/principal-financial-group-inc-grows-holdings-in-aratana-therapeutics-inc-petx/1614399.html.

A number of research firms have issued reports on PETX. ValuEngine cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Lake Street Capital cut their target price on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 25th. BidaskClub cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Jefferies Group LLC set a $8.00 target price on Aratana Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $8.25.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.